adhesion of epithelial ovarian cancer (EOC) cells with improved efficacy compared to the ADH-1 peptide, a Ncadherin antagonist that is in early clinical trials in EOC patients.
Cadherins are a large family of calcium-dependent cell adhesion 15 molecules that are mostly expressed at the intercellular junctions. They are known to play a key role in important physiological processes such as tissue morphogenesis and stability, as well as in the immune system regulation. Over the past 20 years, dysregulation of the type I epithelial E-cadherin (cadh) and 20 neuronal N-cadh have been shown to correlate with tumor progression and other pathological processes. 1 The switch in expression from E-cadh to N-cadh is an important indicator of the epithelial-mesenchymal transition (EMT) occurring during cancer progression. 1 Although E-cadh is considered a repressor for the 25 majority of carcinomas, in epithelial ovarian cancer (EOC) Ecadh persists during tumor progression. 2 We have shown that Eand N-cadh can be co-expressed in some advanced-stage EOCs and that E-cadh expression and homophilic interaction contribute to the proliferation of EOC cells. 2 30 Cadherins from opposing cells interact by means of their extracellular regions, constituted by five Ig-like domains (EC1-EC5), and form multiple trans homophilic dimers arranged in a zipper-like fashion across the cellular adherens junctions. 3, 4 Several X-ray structures of type I and II cadherin ectodomains 5 35 have shown that trans dimerization occurs through the opening of the highly conserved N-terminal six-residue portion of the EC1 (the "adhesion arm") that contains a Trp residue in position 2 (Trp2), and its swapping into an acceptor pocket of the EC1 of the interacting protein, thus resulting in the so-called "strand 40 dimer" formation. However, the complex and highly dynamical cadherin dimerization pathway has only been partially elucidated by the wealth of biochemical and biophysical studies done to date. 4 Ultimately, a variety of transient yet critical key intermolecular interactions involving different residues at 45 different stages of the full cadherin dimerization trajectory play all a critical role in guiding the system through a number of intermediate intermolecular protein-protein arrangements during the recognition process that leads from monomeric cadherin to strand-dimer-formation and back. 6 50 As a result of this highly dynamic behaviour and despite a growing interest in the field, the rational design of small ligands targeting cadherins protein-protein interactions is still in a very early stage. The first crystal structure of the N-cadh EC1 dimer revealed an association interface characterized by the His79-55 Ala80-Val81 (HAV) and the Ile53-Asn54-Pro55 (INP) sequences and not involving the strand swapping portion of the molecule. 7 This triggered an interest in the synthesis of libraries of cyclic peptides based on HAV or INP sequences and of non peptide HAV mimics for the inhibition of the cadherin dimerization 60 process. 8 Among them, the antagonist peptide N-Ac-CHAVC-NH 2 (ADH-1 or Exherin TM , Figure 1 ) containing the HAV motif was promoted to phase I clinical trials in patients with advanced solid tumors which express N-cadh. 9 In this paper, we report the first small library of peptidomimetics 65 based on the tetrapeptide sequence Asp1-Trp2-Val3-Ile4 (DWVI) of the N-and E-cadh N-terminal "adhesive arm". To our knowledge, this work represents the first attempt to rationally design small molecules targeting the strand dimer interfaces identified by recent crystallographic structures. 5 Our compounds 70 were tested in biochemical and functional assays on EOC cells for their ability to inhibit both N-and E-cadh homophilic interactions relative to ADH-1. About 30 peptidomimetics of general formula NH 3 + -Aspscaffold-Ile-NHCH 3 were built in silico by replacing the central 75 dipeptide Trp2-Val3 unit of the DWVI adhesive motif with several scaffolds developed in our and other laboratories ( Figure  2 ). 10, 11 All the peptidomimetics featured a conformationally constrained scaffold bearing a benzyl or phenyl ring to mimic the indole 80 moiety of Trp2 in the native sequence. Based on the molecular architecture of the scaffolds, the aromatic ring was expected to be differently oriented into the binding pocket. To evaluate the ability of each of the compounds of our virtual library to reproduce the DWVI key interactions observed in the X-ray 85 dimer structures ( Figure S1 ) and during Molecular Dynamics simulations ( Figures S2-S3 ), we built a model of the EC1 fragment of E-and N-cadh starting from the corresponding X-ray structures and set up a docking protocol using the Glide V5.7 software 12 (see Supplementary Information). The three ligands were successfully synthesized using conventional high-yielding synthetic pathways in solution and in the solid phase(see Supplementary Information). The compounds were tested by ELISA for their ability to inhibit calcium-dependent cadherin binding using the N-cadh-expressing EOC cell line SKOV3 and N-cadh-Fc chimeric protein. Ligands 2 and 3 at 2 mM concentration inhibited N-cadh homophilic binding by 78% and 84%, respectively, and 50% and 65% at 1 45 mM concentration ( Figure 4A ). Conversely, at 2 mM concentration ADH-1 and 1 provided about 50% inhibition of Ncadh-Fc/cells interactions and appeared nearly ineffective at 1 mM concentration ( Figure 4A ). The compounds were then evaluated for their ability to inhibit EOC cells adhesion by observing the formation of cell monolayers in the presence of each ligand at 2 different concentrations (2 and 1 mM). As with ADH-1, at 2 mM concentration all compounds were able to 5 inhibit the formation of cell monolayers of N-cadh-expressing cells ( Figure S6 ). Notably, 2 and 3 were also active at 1 mM concentration, and 3 was able to inhibit cell-cell aggregation of N-cadh-expressing cells in suspension ( Figure 4B ). When tested on the E-cadh-expressing EOC cell line OAW42, all compounds 10 were found to be less efficient in inhibiting both E-cadh homophilic interactions and the formation of cell monolayers, with significant effects observed only at 2 mM concentration ( Figure S6 and S7) . In particular, by ELISA, at the concentration of 2 mM 1 and 3 gave about 50% inhibition of E-cadh-Fc binding 15 to the cells while ADH-1 showed 30% inhibition ( Figure S7 ), indicating a slightly better efficacy compared to ADH-1 in inhibiting also E-cadh homophilic interactions. Compound 2 was also able to inhibit the formation of cell monolayers at 1 mM concentration ( Figure S6 ). 20 Overall, compounds 2 and 3 resulted to be effective in inhibiting N-cadh homophilic and, to some extent, also E-cadh homophilic adhesion. Encouraged by the very promising results with N-cadhexpressing cells, we set out to evaluate by Surface Plasmon Resonance (SPR) analysis the ability of the two compounds to 25 specifically inhibit the N-cadh homo-dimerization in a cell-free experiment using the N-cadh-Fc recombinant protein. At 10 µM concentrations compounds 2 and 3 provided 98% and 55% inhibition of N-cadh homophilic binding, respectively, while ADH-1 showed only 28% inhibition ( Figure S8) . These data 30 demonstrate the ability of both compounds 2 and 3 to specifically bind to N-cadh even in the µM range. The combination of our computational investigation with the results of SPR assays has started to shed light on the ligand structural requirements for binding to N-cadh. For instance, it 35 appears that the best inhibitors (2 and 3) of N-cadh homophilic binding maintain the key (i) and (ii) interactions and also align with the DWVI backbone ( Figure 3 ). Although N-and E-cadh share similar adhesive binding features for the DWVI sequence 5 and no significant differences were observed in the interaction 40 mode of our peptidomimetic ligands in the two cadherin docking models, the tests on the E-cadh-expressing EOC cell line OAW42 showed lower inhibition capability of E-cadh homophilic binding compared with those of N-cadh. Since a detailed picture of the complete adhesion pathway in the different cadherin family 45 members is still elusive 13 and a variety of factors can contribute to the formation and dissociation of cadherin dimers on cell membranes, our results can be interpreted in light of different considerations. First, two-dimensional affinities measured by micropipette adhesion assays on cell lines expressing E-or N-50 cadhs, 4 have shown that E-cadh homophilic binding is stronger than that of N-cadh. For this reason, our compounds might be less efficient in inhibiting E-cadh than N-cadh interactions. Moreover, based on compelling structural data, 4, 5 we decided to focus exclusively on the inhibition of the swapped-dimer formation 55 targeting the EC1 domain, although several extracellular domains are known to be involved in the formation of highly dynamic and transient protein-protein contacts at the adhesive interface.
It is worth stressing that targeting the interfaces between proteins has huge therapeutic potential, but it still remains a challenge to 60 discover small drug-like molecules that are capable of modulating those protein-protein interactions that are by their nature highly dynamical. In fact, it is clear that the dynamic features of the cadherin dimerization process are likely to play against a traditional drug design approach. Accordingly, the design of a 65 stable molecular interactor against the adhesion pocket would not just prove difficult but it would fail to achieve complete inhibition. However, peptidomimetic molecules that can transiently interfere with structurally validated intermediates in the cadherin dimerization pathway may successfully modulate 70 cadherin-mediated adhesion, even in the absence of an unequivocal identification of the actual binding site and mode.
Conclusions
In this work, we report a first set of peptidomimetic ligands mimicking the adhesive E-and N-cadh DWVI sequence. 75 Remarkably, two of our peptidomimetics inhibit the N-cadhmediated adhesion process in EOC cells with somewhat improved efficacy compared to the ADH-1 cyclic peptide, which is being investigated in phase I clinical trials as a N-cadh antagonist in various tumors, including EOCs. 9 80 Thus, the small molecules generated in the present study are likely to represent new leads for the development of a novel class of modulators of cadherin-mediated adhesion. Such compounds may play an important role in the investigation of cellular processes, and in the design of novel diagnostic and therapeutic 85 approaches against tumors, especially EOCs. Indeed, since the majority of EOCs grow and disseminate in the peritoneal cavity, the locoregional administration of drugs would allow the use of cadherin inhibitors without interfering with the cadherins expressed in normal epithelia. 90 
